Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at #ASCO19; 42% of Patients Achieved a Maximum Reduction of 100% in Target Lesions